Diego, California and at the 53rd European Association for the Studyof Diabetes (EASD) Annual Meeting, September 11 â€“15, 2017, Lisbon, Portugal. Conflict of interest C. G. served as the international coordinating investigator in the trial dis-cussed in this paper, and has participated in scientific advisory boards ofand has received consulting fees fr om Alfa Wasserman, AstraZeneca, Bayer AG, Berlin-Chemie Mennarini , Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi. J. P. F. has received research support fromA b b V i e ,A s t r a Z e n e c a ,B o e h r i n g e rI n g elheim, Bristol-Myers Squibb, Eli Lilly, IONIS, Janssen, Johnson and Johnson, Ligand, Merck, Mylan,Novartis, Novo Nordisk, Pfizer, Sanofi, Theracos and vTv Therapeutics,and has participated in scientific advisory boards of and has receivedconsulting fees from AstraZeneca, Bri stol-Myers Squibb, Novo Nordisk, Sanofi and Theracos. A. S. has no confl icts of interest to report. S. J. has